People | March 28, 2026
Shreehas Tambe appointed CEO & Managing Director of Biocon
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
This recognition demonstrate excellence in intellectual property (IP) value creation.
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Subscribe To Our Newsletter & Stay Updated
